Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cutaneous adverse effects of targeted therapies
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, et al.
Journal of the American Academy of Dermatology (2015) Vol. 72, Iss. 2, pp. 221-236
Closed Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Guidelines of care for the management of primary cutaneous melanoma
Susan M. Swetter, Hensin Tsao, Christopher K. Bichakjian, et al.
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 208-250
Open Access | Times Cited: 568
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
Journal of the American Academy of Dermatology (2016) Vol. 74, Iss. 3, pp. 455-461.e1
Open Access | Times Cited: 290
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Maria E. Cabanillas, Mabel Ryder, Camilo Jiménez
Endocrine Reviews (2019) Vol. 40, Iss. 6, pp. 1573-1604
Open Access | Times Cited: 266
Cutaneous adverse effects of the immune checkpoint inhibitors
Lindsey K. Collins, Michael Chapman, Joi B. Carter, et al.
Current Problems in Cancer (2016) Vol. 41, Iss. 2, pp. 125-128
Closed Access | Times Cited: 205
Vitiligo Pathogenesis and Emerging Treatments
Mehdi Rashighi, John E. Harris
Dermatologic Clinics (2017) Vol. 35, Iss. 2, pp. 257-265
Open Access | Times Cited: 187
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Émmanuelle Vigarios, Joel B. Epstein, V. Sibaud
Supportive Care in Cancer (2017) Vol. 25, Iss. 5, pp. 1713-1739
Open Access | Times Cited: 163
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
Chun‐Bing Chen, Ming-Ying Wu, Chau Yee Ng, et al.
Cancer Management and Research (2018) Vol. Volume 10, pp. 1259-1273
Open Access | Times Cited: 137
Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch
Yong Chen, Quan Fang, Zilong Wang, et al.
Journal of Biological Chemistry (2016) Vol. 291, Iss. 19, pp. 10252-10262
Open Access | Times Cited: 121
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
Neeraj Chhabra, Joseph M. Kennedy
Journal of Medical Toxicology (2021) Vol. 17, Iss. 4, pp. 411-424
Open Access | Times Cited: 100
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
Mario E. Lacouture, V. Sibaud, Peter Arne Gerber, et al.
Annals of Oncology (2020) Vol. 32, Iss. 2, pp. 157-170
Open Access | Times Cited: 94
Cutaneous adverse events caused by immune checkpoint inhibitors
Henry T. Quach, Douglas B. Johnson, Nicole R. LeBoeuf, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 4, pp. 956-966
Closed Access | Times Cited: 90
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer
Richard L. Carpenter, Haimanti Ray
Drug Safety (2019) Vol. 42, Iss. 2, pp. 263-279
Open Access | Times Cited: 86
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Mohammad Al-Jundi, Shilpa Thakur, Sriram Gubbi, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2104-2104
Open Access | Times Cited: 73
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
A. Martens, Pieter‐Paul Schauwvlieghe, A. Madoe, et al.
Journal of Ophthalmic Inflammation and Infection (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Study on mechanism of Spatholobi Caulis in the treatment of the hand-foot skin reaction induced by targeted drug therapy based on network pharmacology and molecular docking: An observational study
Quan‐yao Li, Huannan Meng, Li-qiu Yao, et al.
Medicine (2025) Vol. 104, Iss. 2, pp. e41085-e41085
Open Access | Times Cited: 1
Cutaneous Complications of Targeted Melanoma Therapy
Emily de Golian, Bernice Y. Kwong, Susan M. Swetter, et al.
Current Treatment Options in Oncology (2016) Vol. 17, Iss. 11
Closed Access | Times Cited: 74
A clinical and biological review of keratoacanthoma*
Aaron Tisack, Audrey Fotouhi, Chelsea Fidai, et al.
British Journal of Dermatology (2021) Vol. 185, Iss. 3, pp. 487-498
Closed Access | Times Cited: 43
Drugs and the skin: A concise review of cutaneous adverse drug reactions
Blanca R. Del Pozzo‐Magaña, Carmen Liy‐Wong
British Journal of Clinical Pharmacology (2022) Vol. 90, Iss. 8, pp. 1838-1855
Open Access | Times Cited: 32
TNF stimulates IL‐6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin
Arti Patel, Irene Tsilioni, Zuyi Weng, et al.
Experimental Dermatology (2017) Vol. 27, Iss. 2, pp. 135-143
Closed Access | Times Cited: 52
Systemic Therapies for Advanced Melanoma
Leonora Bomar, Aditi Senithilnathan, Christine Ahn
Dermatologic Clinics (2019) Vol. 37, Iss. 4, pp. 409-423
Closed Access | Times Cited: 52
Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy
Alana Deutsch, Nicole R. LeBoeuf, Mario E. Lacouture, et al.
American Society of Clinical Oncology Educational Book (2020), Iss. 40, pp. 485-500
Closed Access | Times Cited: 46
Potential Successes and Challenges of Targeted Cancer Therapies
Dorothy Keefe, Emma Bateman
JNCI Monographs (2019) Vol. 2019, Iss. 53
Closed Access | Times Cited: 45
Personalized targeted therapy for esophageal squamous cell carcinoma
Xiaozheng Kang
World Journal of Gastroenterology (2015) Vol. 21, Iss. 25, pp. 7648-7648
Open Access | Times Cited: 48
Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis
Ling Peng, Yina Wang, Yun Hong, et al.
Oncotarget (2017) Vol. 8, Iss. 47, pp. 83280-83291
Open Access | Times Cited: 45
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
Sohita Dhillon
Targeted Oncology (2016) Vol. 11, Iss. 3, pp. 417-428
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top